期刊
NATURE MEDICINE
卷 16, 期 3, 页码 313-U110出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.2101
关键词
-
资金
- NIDDK NIH HHS [P01 DK074868-030001, R01 DK091183, DK007202, P30 DK063491, P30 DK063491-019003, P01DK074868, P01 DK074868-029001, T32 DK007202, P01 DK074868, DK063491, P01 DK074868-01A1] Funding Source: Medline
- NIGMS NIH HHS [U54 GM069338-010002, GM 069338-03, U54 GM069338] Funding Source: Medline
Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (encoded by Cftr) that impair its role as an apical chloride channel that supports bicarbonate transport(1). Individuals with cystic fibrosis show retained, thickened mucus that plugs airways and obstructs luminal organs(2) as well as numerous other abnormalities that include inflammation of affected organs(1), alterations in lipid metabolism(3) and insulin resistance(4). Here we show that colonic epithelial cells and whole lung tissue from Cftr-deficient mice show a defect in peroxisome proliferator activated receptor-gamma (PPAR-gamma, encoded by Pparg) function that contributes to a pathological program of gene expression. Lipidomic analysis of colonic epithelial cells suggests that this defect results in part from reduced amounts of the endogenous PPAR-gamma ligand 15-keto-prostaglandin E(2) (15-keto-PGE(2)). Treatment of Cftr-deficient mice with the synthetic PPAR-gamma ligand rosiglitazone partially normalizes the altered gene expression pattern associated with Cftr deficiency and reduces disease severity. Rosiglitazone has no effect on chloride secretion in the colon, but it increases expression of the genes encoding carbonic anhydrases 4 and 2 (Car4 and Car2), increases bicarbonate secretion and reduces mucus retention. These studies reveal a reversible defect in PPAR-gamma signaling in Cftr-deficient cells that can be pharmacologically corrected to
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据